← Back to Search

CD40 Agonist

2141 V-11 for Cancer

Phase 1

Waitlist Available

Led By David A Knorr, MD, PhD

Research Sponsored by Rockefeller University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, an average of 2 years

Awards & highlights

Study Summary

This trial is testing the safety and effectiveness of a new drug, 2141-V11, for people with cancer that has spread to the skin. The drug activates a protein called CD40, which helps the immune system kill cancer cells.

Eligible Conditions

Cancer
Skin Cancer
Solid Tumors

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion, an average of 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion, an average of 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change from baseline laboratory assessments and toxicities over time in abnormal Complete Blood Count labs and Complete Metabolic Panel labs assessed by SI laboratory reference ranges

Changes from baseline in anti-drug antibody (ADA) responses to 2141-V11 exposure over time

Incidence and severity of DLTs reported and their relationship to 2141-V11 administration assessed by NCI CTCAE v4.03

+1 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Injection of 2141-V11Experimental Treatment1 Intervention

Open label study drug 2141-V11 at escalating doses until MTD is determined, and expansion utilizing the MTD.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

2141 V-11

2020

Completed Phase 1

~20

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Rockefeller UniversityLead Sponsor

158 Previous Clinical Trials

16,341 Total Patients Enrolled

David A Knorr, MD, PhDPrincipal InvestigatorRockefeller University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still open positions in this research study?

"The clinical trial, which was posted on 1/16/2020 and updated as recently as 3/15/2022 according to information from clinicaltrials.gov, is searching for participants."

Answered by AI

What is the most recent news on whether 2141 V-11 has been cleared by the FDA?

"2141 V-11 is still in Phase 1 of clinical trials, so there is limited data to support its safety. However, it did receive a score of 1 from our team at Power."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study Investigating the Safety and Tolerability of an Immune Treatment in Cancer Patients With Lesions to the Skin

2020. "A Study Investigating the Safety and Tolerability of an Immune Treatment in Cancer Patients With Lesions to the Skin". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04059588.